Condition: Sickle Cell Disease · Sponsor: Kamau Therapeutics
This study is a first-in-human, single-arm, open-label Phase I/II study of nula-cel in approximately 15 participants, diagnosed with severe Sickle Cell Disease. The primary objective is to evaluate safety of the treatment in this patient population, as well as preliminary efficacy and pharmacodynamic data.
This description comes directly from the study's public registry record.
Restore Clinical Study Support · 650-442-2283 · RestoreStudySupport@kamautx.com
Always discuss trial participation with your own doctor first.
| Children's Hospital Los Angeles | Los Angeles, California, United States | Recruiting |
| Lucile Packard Children's Hospital | Palo Alto, California, United States | Recruiting |
| Washington University | St Louis, Missouri, United States | Recruiting |
| Columbia University Irving Medical Center | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering | New York, New York, United States | Recruiting |
| Nationwide Children's Hospital | Columbus, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04819841